Atera is moving into the hands of researchers around the world, from those scaling existing spatial programs to researchers exploring spatial biology for the first time, across discovery, translational and biopharma research.

Atera's growing reach is matched by the breadth of research now being planned on the platform, spanning biological questions across nearly every major disease area, from oncology and neurodegenerative disease, to autoimmune, inflammatory and cardiometabolic disease and more. Planned applications include foundational cell and tissue atlasing, studies of disease mechanisms and therapeutic response, biomarker research and the generation of large-scale datasets to train AI models of biology.

Demand for Atera has been extraordinary from the start. As previously announced at the company's second-quarter earnings call, booked orders exceeded the 40 instruments that 10x expected to ship in 2026. Since then, momentum has continued to build. Now, as the first instruments begin shipping, that demand is translating into ambitious new research programs designed to take advantage of Atera's combination of breadth, sensitivity and scale.